Frontiers in Medicine (Nov 2023)

Prolonged survival of a patient with active MDR-TB HIV co-morbidity: insights from a Mycobacterium tuberculosis strain with a unique genomic deletion

  • Mor Rubinstein,
  • Andrei Makhon,
  • Yelena Losev,
  • Gal Zizelski Valenci,
  • Yair E. Gatt,
  • Hanah Margalit,
  • Ephraim Fass,
  • Ina Kutikov,
  • Omer Murik,
  • David A. Zeevi,
  • Michal Savyon,
  • Luba Tau,
  • Luba Tau,
  • Hasia Kaidar Shwartz,
  • Zeev Dveyrin,
  • Efrat Rorman,
  • Israel Nissan

DOI
https://doi.org/10.3389/fmed.2023.1292665
Journal volume & issue
Vol. 10

Abstract

Read online

Coinfection of HIV and multidrug-resistant tuberculosis (MDR-TB) presents significant challenges in terms of the treatment and prognosis of tuberculosis, leading to complexities in managing the disease and impacting the overall outcome for TB patients. This study presents a remarkable case of a patient with MDR-TB and HIV coinfection who survived for over 8 years, despite poor treatment adherence and comorbidities. Whole genome sequencing (WGS) of the infecting Mycobacterium tuberculosis (Mtb) strain revealed a unique genomic deletion, spanning 18 genes, including key genes involved in hypoxia response, intracellular survival, immunodominant antigens, and dormancy. This deletion, that we have called “Del-X,” potentially exerts a profound influence on the bacterial physiology and its virulence. Only few similar deletions were detected in other non-related Mtb genomes worldwide. In vivo evolution analysis identified drug resistance and metabolic adaptation mutations and their temporal dynamics during the patient’s treatment course.

Keywords